Paul Hartmann AG (DE0007474041) – Back to my (boring) roots
Paul Hartmann AG is a 200 year old German company active in the healthcare sector, This is how they describe themselves:
The HARTMANN GROUP is a global company operating in the field of medical and care products. The core of the product portfolio offered under the HARTMANN brand is formed by professional system solutions in the areas of wound management, incontinence hygiene, and infection protection. Complementary products and supplementary services round out the range for medicine and hygiene.
The focus is on products and services for professional users in hospitals, doctors’ practices, nursing homes, and for home-care services. HARTMANN offers innovative all-in-one solutions made up of user-friendly products and fit-to-purpose services – helping in this way to make everyday work to enhance patients’ wellbeing
that bit more efficient and cost-effective. The company also offers consumer product ranges sold at pharmacies and specialist medical stores.
Back to my roots:
I owned Hartmann long time again and sold it in 2010 just before I started the blog. I sold it at that time because the stock price went up a lot in short time and I started to move from my “core center of competence” German small caps to more international targets.
Facts & Figures:
Market Cap: 1,2 bn EUR
PE (2017): 13,4
Dividend yield 2,1%
EV/EBITDA (2017) ~6,5 (including pensions)
Debt: Net cash
Free float: Unknown (below 50%)
The company is not covered by any analysts. The stock is traded at a very lightly regulated segment of the German stock market. therefore information requirements are limited, for instance only sharholder transactions above 10% have to be notified.
Looking at the stock chart we can clearly see that things looked Ok until 2017 (compared to the MDAX) but than the stock started dropping and has lost more than 30% over the last 12 months.
This is mostly the result of a profit warning from September 2017, where the company said that this is mainly due to the new European Medical Device Regulation (MDR) that leads to extra cost. I haven’t been aware of this new regulation but this E&Y report confirms that this is “for real”:
The costs associated with compliance may force some companies putting themselves up for sale. The aftermath of the shake- up will be a stronger, more accountable medtech industry that may look substantially different from today’ s. Many medtech companies have begun to look at how they should address compliance, and realized that the extent of the changes requires a company- wide approach. These companies have grasped that the EU MDR represents not just a compliance
challenge, but an opportunity to add value to the business at the same time.
In regulated industries, an increase in regulation often has two effects on the existing players: Yes, it increase cost but also in the long run it often makes it more difficult for others to enter the space. It will be interesting to see how this plays out for Hartmann, but at the moment it looks like the costs are significant.
In Q1 2018, EBITDA dropped yoy by -8%, EBIT by -16% and net income even by -17,5%. As Hartmann is only listed in a very lightly regulated segment of the German stock market, no detailed numbers are available to really understand the drop in profit. The language in the report says however that they expect a “Moderate drop” in EBIT for 2018.
The company is really boring:
A German stock blog writer for instance sold the stock last year (well-timed by the way) among other reasons that the company was “snoring”. In the same posts a commentator argued that he didn’t like the stock as the majority shareholder (Schwenk family) is not interested in more aggressive strategies as they like Hartmann to be defensive in order to compensate for their main cyclical Cement/building material.
What I like about the company:
+ the company is run conservatively: Net cash, few M&A transactions. long-term orientation
+ the company is in a stable sector with long-term growth
+ the current weakness seems to be triggered by an industry wide issue
+ despite its size it is mostly unknown (no index member etc.)
+ very moderately valued
– the industry is really hard and regulated (cost saving pressure at main clients)
– mediocre returns on capital
– relatively large pension reserves
– no short-term catalysts
Some historical numbers:
This is for instance the development of net debt since 2011:
|Net debt incl. pension||-120.8||-99.7||-121||-145.8||-182.3||-203.9||-247.1|
It is easy to see that Paul Hartmann “delivered” the company over the past 8 years until last year when Net cash went slightly down after their first larger acquisition for a long time. The acquisition was a Spanish decision of P&G specialized in producing and selling incontinency products via pharmacies. Although the acquisition looks expensive compared to Hartmann’s own valuation, from a strategic point of view it looks ok, as this is clearly within the core market of Hartmann.
A Private Equity owner would have done most likely the exact opposite It would have been relatively easy to obtain low yielding debt and either buy back shares or buy higher margin businesses. This often works in the short run, but creates problems in the long run makes companies vulnerable.
Interestingly, Hartmann’s Swiss subsidiary has its stock listed on the Swiss stock exchange.
IVF has a market cap of 440 mn CHF and trades on much higher multiples that the German Holdco:
P/E 2017: 27,4
P/S : 3,3
However, IVF Hartmann is also much more profitable. EBIT margins are on average 14% or 2x that of Paul Hartmann. I honestly do not know why. Maybe the Swiss market is more regulated and margins therefore higher ?
As always, I try to keep it simple. At the current stock price the earnings yield is around 6-7%. Free cashflow yield is even a little bit higher.
Assuming a long-term growth rate of 3-5% p.a. I would estimate at the current share price a potential long-term return of between 9-12% p.a. This doesn’t sound much, but in relation to the “antifragile” business model I do thin this is attractive from a risk return perspective.
I have therefore allocated ~2% of my portfolio into Paul Hartmann shares as a starter position at ~334 EUR/share and I plan to add slowly over the coming months.